比起肿瘤领域,目前mRNA在流感上的临床进度稍快一些,在RSV等适应症上推进到了三期临床阶段,2023年1月18日,Moderna宣布一种针对老年人呼吸道合胞病毒(RSV)的mRNA疫苗mRNA-1345,在关键性3期临床试验ConquerRSV中获得积极顶线结果。经过独立的数据和安全监测委员会(DSMB)的审查,已达到主要疗效终点,目前已经在多个国家递...
剂量设计更加精细的研究也已出现,例如预防CMV的mRNA-1647在I期临床试验中,设置了30、90、180、300μg剂量(mRNA-1647或安慰剂),分别在0、2、6个月注射三次【15】。正在进行I期临床的RSV疫苗mRNA-1345也设计三次免疫,分别间隔2个月,目前正以单次剂量进行临床III期试验。 尽管技术和抗原选择类似,开发中的新冠病...
1.As commercial COVID pivotlooms, Moderna logs $2.8 B in demand-related expenses;FIERCE PHARMA 2.Pfizer, Moderna set to tangle in COVID vaccine patent trial next April: reports;FIERCE PHARMA 3.新冠疫苗专利之争再升级,辉瑞/BioNTech要求判决Moderna主张无效;同写意 4.Moderna vs 辉瑞:那些从新冠淘金...
Self-amplifying mRNA vaccines, such as ARC-021 and BNT162c2, are intended to be given as a single dose. More elaborate regimens have also been described. For instance, mRNA-1647, directed against CMV, was administered in a phase 1 study (NCT03382405) to healthy volunteers, who received thr...
Respiratory syncytial virus (RSV) mRNA-1345 mRNA encoding a prefusion F glycoprotein [LNP] I Moderna (US) NA 3 doses 56 d apart NCT04528719 Cytomegalovirus (CMV) mRNA-1647 [i.d.] CMV glycoprotein H (gH) pentamer complex and gB protein [LNP] II Moderna (US) NA Day 1, Day 56, Day...
and D.G.A. have filed a patent for the use of C3d in mRNA vaccines. D.G.A receives research funding from Sanofi/Translate Bio and is a co-founder of Orna Therapeutics. R.L. co-founded Moderna and serves on its board. He has been an advisor for Hopewell Therapeutics and Combined ...
Although inoculation of COVID-19 vaccines has rolled out globally, there is still a critical need for safe and effective vaccines to ensure fair and equitable supply for all countries. Here, we report on the development of a highly efficacious mRNA vacci
Core Patent Boost your research with our Core Patent data. login or view full example data Clinical Trial Identify the latest clinical trials across global registries. login or view full example data Approval Accelerate your research with the latest regulatory approval information. ...
正在进行I期临床的RSV疫苗mRNA-1345也设计三次免疫,分别间隔2个月,目前正以单次剂量进行临床III期试验。 尽管技术和抗原选择类似,开发中的新冠病毒mRNA疫苗剂量范围很广。基于所用技术,自扩增型mRNA疫苗每一剂的用量较少:皇家学院的自扩增疫苗测试剂量介于0.1-1 μg。ARCT-021曾测试1-10 μg剂量,分别设计单剂...